



**Molecular Diagnostics Requisition**

Test requested by: \_\_\_\_\_

Patient name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date of birth: \_\_\_\_/\_\_\_\_/\_\_\_\_

Date requested: \_\_\_\_/\_\_\_\_/\_\_\_\_

Pathology No: \_\_\_\_\_

Tel: \_\_\_\_\_ Fax: \_\_\_\_\_

Pathology barcode

Clinical history and provisional diagnosis:

Tissue source: \_\_\_\_\_ Date requested: \_\_\_\_/\_\_\_\_/\_\_\_\_ Date received: \_\_\_\_/\_\_\_\_/\_\_\_\_

Tissue Preparation:  Paraffin (part# \_\_\_\_\_ block# \_\_\_\_\_)  Frozen in OCT  Fresh (RPMI)  Brush tip in ETOH

**Tissue/Specimen Preparation**

*Fresh or Frozen Tissue:* Please call the lab for instructions.

*Fixed Tissue:* Paraffin block(s) or ten unstained sections 5 µm thick (on charged slides if FISH analysis is ordered) or more, depending on tissue volume. Submission of acid-decalcified tissue specimen is discouraged.

Please check the box(es) for test(s) requested:

**PCR Tests**

- BRAF mutation testing (exon 15)**  
(Thyroid carcinoma, hairy cell leukemia and other solid tumors)
- DNA extraction**
- EGFR mutation testing (exons 18-21)**  
(NSCLC)
- FOXL2 mutation testing (exon 1)**  
(Granulosa cell tumor and other ovarian neoplasms)
- Immunoglobulin heavy chain gene rearrangement/Clonality analysis** (B cell lymphoma)
- KIT (c-Kit) mutation testing (exons 9, 11, 13, 17, 18)**  
(GIST, melanoma and other solid tumors)
- KRAS mutation testing (exon 2)**  
(Solid tumors and precancerous lesions)
- MGMT promoter DNA methylation**  
(Gliomas)
- MLH1 methylation**  
(Screening tool for Lynch syndrome)
- Microsatellite instability analysis (MSI)**  
(HHPCC/Lynch syndrome)
- Mycobacterium tuberculosis**  
(TB infection)
- T-cell receptor gene rearrangement/Clonality analysis**  
(T cell lymphoma)
- ThyroSure Gene Panel**  
(PCR/NGS for thyroid carcinoma)
- Tissue DNA fingerprinting/Genotyping**  
(Identity testing and hydatidiform moles)

**FISH Tests**

- ALK chromosomal rearrangement/translocation/inversion**  
(Anaplastic large cell lymphoma and non-small cell lung cancer)
- BCL1 gene rearrangement/translocation t(11;14)**  
(Mantle cell lymphoma)
- BCL2 gene rearrangement/translocation t(14;18)**  
(Follicular cell lymphoma)
- BCL6 gene rearrangement**  
(B cell lymphomas)
- Chromosome 1p/19q deletion**  
(Oligodendroglioma)
- EGFR amplification**  
(Glioblastoma and other brain tumors)
- EWS chromosomal rearrangement/translocation**  
(Ewing's sarcoma/PNET, DSRCT, extraskeletal myxoid chondrosarcoma, and clear cell sarcoma of soft part)
- HER2/ERBB2 amplification**  
(Breast and other solid tumors)
- MDM2 amplification**  
(Soft tissue sarcoma)
- MET chromosomal amplification**  
(Non-small cell lung cancer)
- MYC gene rearrangement/translocation**  
(Burkitt's lymphoma and subset of diffuse large B cell lymphoma)
- RET chromosomal rearrangement/translocation**  
(Non-small cell lung cancer)
- ROS1 chromosomal rearrangement/translocation**  
(Non-small cell lung cancer)
- SYT gene rearrangement/translocation t(X;18)**  
(Synovial sarcoma)
- TFE3 gene rearrangement**  
(Renal cell carcinoma)
- UroVysion**  
(Urothelial carcinoma)

Please forward this form and billing information to: Yale Pathology Labs, Clinic Building, 310 Cedar Street, 5th Floor, New Haven, CT 06510  
 Tel 203-785-4492 or 203-737-2533, Fax 203-785-3896

For all medical issues, contact: Pei Hui, MD, PhD, Clinical Director, Molecular Diagnostics Lab, Tel 203-785-6498, Mobile Heartbeat: 475-224-8201